Study Says Bird-Flu Vaccine Comparison Tests Vary Too Much
This article was originally published in PharmAsia News
Executive Summary
A British study warns drug makers the tests they conduct to determine the effectiveness of their avian influenza vaccines may not be as true as previously thought. The study looked at the tests vaccine makers use and said the sensitivity of the tests varies according to values used. That, researchers said, could lead the pharmas to over- or under-estimate the effectiveness of their vaccine's smallest dose for protection when compared with a competitor. One expert said the study means an effort should be made to develop a consensus on the values to be measured in such tests. (Click here for more
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.